Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Fezolinetant in Renal Impairment
NCT04476849Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fezolinetant in vasomotor symptoms (4 arms), sponsored by Astellas Pharma. Primary endpoints: Area Under the Concentration-time Curve From Time Zero to Infinity up to 5 days, Area Under the Concentration-time Curve From Time Zero to Last Measurable Concentration up to 5 days and 2 more. Started Aug 2020; status: completed.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT04476849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04476849.